Drugs / CDA-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03335943 | Dec 2017 → Dec 2019 | myelodysplastic syndrome | Chinese Society of Hematology | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDA-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03335943 ↗ |
| Known as | Cell Differentiation Agent 2 | “CDA-2 (Cell Differentiation Agent 2)” NCT03335943 ↗ |
| Modality | Other / unclassified | “a compound mixed of peptides and organic acids” NCT03335943 ↗ |
| Route | Intravenous | “CDA-2 will be given intravenously” NCT03335943 ↗ |